Search results for "Postmenopausal"

showing 10 items of 92 documents

Influence of long-term postmenopausal hormone replacement therapy on estimated structural bone strength: A study in discordant monozygotic twins.

2011

Although postmenopausal hormone-replacement therapy (HRT) is known to prevent fractures, knowledge on the influence of long-term HRT on bone strength and its determinants other than areal bone mineral density is scarce. This study used a genetically controlled design with 24 monozygotic female twin pairs aged 54 to 72 years in which one cotwin was using HRT (mean duration 8 years) and the other had never used HRT. Estimated bone strength, cross-sectional area, volumetric bone mineral density, bone mineral mass, and cross-sectional density and mass distributions were assessed in the tibial shaft, distal tibia, and distal radius with peripheral computed tomography (pQCT). In the tibial shaft,…

luustoidenttiset kaksosetluuvaihdevuosien jälkeinen hormonikorvaushoitopostmenopausal hormone replacement therapy
researchProduct

Genetic and environmental contributions to bone structural strength in postmenopausal women

2010

mechanical loadingluustonaisetpostmenopausalexercisehormone therapytwinsbone strengthgenetic effectliikuntalonkkafyysinen kuormittavuusikääntyminenhip fractureperimämuscle strengthhormonihoitotasannevuodetwomenluunmurtumatlujuusikääntyneetlihasvoima
researchProduct

Effects of soy isoflavones on endothelial function in healthy postmenopausal women.

2005

Objective: To evaluate the effects of soy isoflavone administration on endothelial function in healthy postmenopausal women. Design: Sixty naturally postmenopausal women were randomly assigned to receive isoflavone or placebo tablets for 6 months. Endothelium-dependent vasodilatation was measured by brachial reactivity technique along with levels of plasma soluble intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, P-selectin and soluble thrombomodulin, von Willebrand factor, and tissue plasminogen activator. Differences between endothelium-dependent and endothelium-independent vasodilatation were assessed by evaluating brachial reactivity par…

medicine.medical_specialtyAdhesion moleculeEndotheliumBrachial ArteryGenisteinVascular Cell Adhesion Molecule-1PhytoestrogensFibrinogenAdhesion molecule; Endothelial function; Postmenopausal womenchemistry.chemical_compoundVon Willebrand factorInternal medicineMedicineHumansProspective StudiesReactive hyperemiabiologybusiness.industryObstetrics and GynecologyEndothelial functionIsoflavonesMiddle AgedIntercellular Adhesion Molecule-1Postmenopausal womenIsoflavoneGenisteinIsoflavonesDietPostmenopauseVasodilationProspective StudieP-SelectinEndocrinologymedicine.anatomical_structurechemistryPhytoestrogencardiovascular systembiology.proteinFemaleEndothelium VascularSoybeansSoybeanbusinessE-SelectinPlasminogen activatorHumanLipoproteinmedicine.drugMenopause (New York, N.Y.)
researchProduct

Current management of pelvic organ prolapse in aging women : EMAS clinical guide

2018

Management of pelvic organ prolapse (POP) is a common and challenging task. Nowadays older women are more active than they were in the past, and the development of POP disrupts quality of life and impairs social and personal activities. The menopausal transition is a time of vulnerability, during which many women start experiencing symptoms and signs of POP. The role of hormonal changes or of hormonal therapies in influencing the development or progression of POP has been explored extensively. The management of POP requires considerable clinical skills. Correct diagnosis and characterization of the prolapse and an identification of the individual woman's most bothersome symptoms are the hal…

medicine.medical_specialtyAginggenetic structuresFLOOR DISORDERSUrinary incontinenceUrinary incontinencebehavioral disciplines and activitiesGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialMultidisciplinary approachlawQUALITY-OF-LIFE3123 Gynaecology and paediatricsmedicineHumans030212 general & internal medicineIntensive care medicineGENITOURINARY SYNDROMECompetence (human resources)AgedICS JOINT REPORTPelvic organ030219 obstetrics & reproductive medicineVULVO-VAGINAL ATROPHYbusiness.industryObstetrics and GynecologyLAPAROSCOPIC LATERAL SUSPENSIONERYAG LASER TREATMENTmedicine.diseaseSTRESS URINARY-INCONTINENCEOptimal management3. Good healthPelvic organ prolapseManagementMenopauseAging; Management; Pelvic organ prolapse; Urinary incontinenceCurrent managementPOSTMENOPAUSAL WOMEN3121 General medicine internal medicine and other clinical medicineRANDOMIZED-CONTROLLED-TRIALFemaleMenopausemedicine.symptombusiness
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Association between low-frequency ultrasound and hip fractures - comparison with DXA-based BMD

2013

Background New methods for diagnosing osteoporosis and evaluating fracture risk are being developed. We aim to study the association between low-frequency (LF) axial transmission ultrasound and hip fracture risk in a population-based sample of older women. Methods The study population consisted of 490 community-dwelling women (78–82 years). Ultrasound velocity (VLF) at mid-tibia was measured in 2006 using a low-frequency scanning axial transmission device. Bone mineral density (BMD) at proximal femur measured using dual-energy x-ray absorptiometry (DXA) was used as the reference method. The fracture history of the participants was collected from December 1997 until the end of 2010. Lifestyl…

medicine.medical_specialtyBone densityCortical boneOsteoporosisPopulationDentistryRisk AssessmentHip fractureAbsorptiometry PhotonRheumatologyBone DensityPredictive Value of TestsRisk FactorsmedicineHumansOrthopedics and Sports MedicineProspective StudieseducationOsteoporosis PostmenopausalAgedUltrasonographyFemoral neckAged 80 and overBone mineralHip fractureeducation.field_of_studyTibiaFemur NeckHip Fracturesbusiness.industryOdds ratiomedicine.diseaseFractures Spontaneousmedicine.anatomical_structureSpeed of soundOsteoporosisFemaleRadiologybusinessRisk assessmentQuantitative ultrasoundFollow-Up StudiesResearch ArticleBMC Musculoskeletal Disorders
researchProduct

Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women

2003

Objective: It is conceivable that, since menopause accelerates the continuous bone loss determined by age, a specific configuration of bone mass determinants during the first postmenopausal years occurs. Methods: To establish their value as indicators of bone mass in women with recent natural menopause, we assessed relationships between bone mineral density (BMD) and age, menopausal age, body mass index (BMI), PTH, sex steroid hormones (estradiol and testosterone), and several markers of bone turnover in urine (N-telopeptide and calcium/creatinine ratio) or serum (osteocalcin (OC), total alkaline phosphatase (ALP), total and ionic calcium (iCa), phosphate (P) and magnesium (Mg)) for a group…

medicine.medical_specialtyBone diseaseBone densityOsteocalcinOsteoporosisParathyroid hormoneCollagen Type IGeneral Biochemistry Genetics and Molecular BiologyBody Mass IndexPhosphatesBone remodelingBone DensityReference ValuesInternal medicinemedicineHumansMagnesiumTestosteroneOsteoporosis PostmenopausalFemoral neckBone mineralEstradiolbusiness.industryObstetrics and GynecologyMiddle AgedAlkaline Phosphatasemedicine.diseaseMenopauseEndocrinologymedicine.anatomical_structureParathyroid HormoneCreatinineCalciumFemaleCollagenPeptidesbusinessBiomarkersMaturitas
researchProduct

Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

1997

Two hundred and fifty-five postmenopausal women with distal forearm bone mineral density (BMD) 1 SD below the mean value for normal age-matched postmenopausal subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d.) or a matched placebo, according to a double-masked, parallel-group design. All patients also received a 1 g/day calcium supplement. Distal radius BMD and bone metabolism markers were measured at baseline, and every 6 months. Blood haematology and chemistry and physical parameters were monitored at the same time. One hundred and ninety-six patients completed 2 years of treatment. BMD changes from baseline were analysed according to valid comple…

medicine.medical_specialtyBone diseaseEndocrinology Diabetes and MetabolismOsteoporosisUrologyPlaceboBone and BonesBone remodelingchemistry.chemical_compoundBone DensityHumansMedicineOsteoporosis PostmenopausalAgedBone mineralCreatinineIntention-to-treat analysisbusiness.industryMiddle Agedmedicine.diseaseIsoflavonesSurgeryHydroxyprolineRadiuschemistryFemaleIpriflavonebusinessmedicine.drug
researchProduct

Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women

2006

To investigate the effects of a low transdermal estradiol dose on bone metabolism and to compare it with both the standard dose and absence of treatment.In this study performed in a third-level academic center, 66 healthy postmenopausal women underwent hormone therapy (HT) with patches containing estradiol at standard (0.050 mg/day, HT50, 33 women) or low dosage (0.025 mg/day, HT25, 33 women) and 70 women were without treatment (NT). The values (mean of three samples) of several bone biochemical parameters were compared between groups after adjusting for confounding factors. Bone mineral density (BMD) was assessed (by dual-energy X-ray absorptiometry) in the spine and hip in all cases, and …

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisCollagen Type IBone remodelingEndocrinologyBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalTransdermalBone mineralAnalysis of VarianceDose-Response Relationship DrugEstradiolbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedAlkaline Phosphatasemedicine.diseasePostmenopauseMenopauseDose–response relationshipEndocrinologyFemaleHormone therapyPeptidesDensitometrybusinessBiomarkersGynecological Endocrinology
researchProduct

FokI Polymorphism of the Vitamin D Receptor Gene Correlates with Parameters of Bone Mass and Turnover in a Female Population of the Italian Island of…

2005

One of the most promising genetic approaches to dissecting a multifactorial disease is represented by genetically isolated population studies. We studied a genetic marker in a cohort of women living on the Mediterranean island of Lampedusa, a geographically isolated population. Lampedusa, located between the African coast and Sicily, consists of a young genetic isolate (<20 generations) with an exponential growth in the last generations. We analyzed the association between the FokI vitamin D receptor (VDR) gene polymorphism, previously proposed as a predictor of bone mass, with parameters of bone mass and turnover in a cohort of pre- and postmenopausal women living on Lampedusa. In 424 wome…

medicine.medical_specialtyGenotypeBone densityEndocrinology Diabetes and MetabolismOsteoporosisCalcitriol receptorBone and BonesWhite PeopleCohort StudiesFokI polymorphism of the vitamin DEndocrinologyGene FrequencyBone DensityRisk FactorsInternal medicineGenotypemedicineHumansOrthopedics and Sports MedicineAllele frequencyOsteoporosis PostmenopausalUltrasonographyPolymorphism GeneticbiologyExonsMiddle Agedmedicine.diseaseFokIPostmenopauseEndocrinologyItalyPremenopauseOsteocalcinbiology.proteinReceptors CalcitriolFemaleGene polymorphismCalcified Tissue International
researchProduct